PDCD1 and Burkitt lymphoma: Based on these findings, we hypothesized that in order to enhance the therapeutic efficacy of EZH2 inhibition in Burkitt’s lymphoma within an immune cell-rich environment, it is crucial to limit the activity of PD-L1 using anti-PD-1 (aPD1) treatment.